Publications by authors named "Tess Moore Calcagno"

Article Synopsis
  • Anti-TNF-α agents are used as a third-line treatment for patients with refractory sarcoidosis, but previous studies report mixed results regarding their effectiveness.
  • A systematic meta-analysis was conducted to evaluate the efficacy of these agents on both pulmonary and extra-pulmonary sarcoidosis, utilizing data up to April 2022 from several medical databases.
  • The analysis included eight clinical trials, showing a treatment success rate of approximately 69.9% for pulmonary sarcoidosis and 74.5% for extrapulmonary sarcoidosis, suggesting that anti-TNF-α agents can be effective in managing symptoms and preventing disease progression.
View Article and Find Full Text PDF

The 2019 novel coronavirus (COVID-19) has been declared a public health emergency worldwide. The objective of this systematic review was to characterize the clinical, diagnostic, and treatment characteristics of hospitalized patients presenting with COVID-19. We conducted a structured search using PubMed/Medline, Embase, and Web of Science to collect both case reports and case series on COVID-19 published up to April 24, 2020.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Tess Moore Calcagno"

  • - Tess Moore Calcagno's recent research primarily focuses on the efficacy of medical treatments in managing complex health conditions, including sarcoidosis and post-traumatic stress disorder (PTSD).
  • - In her 2023 meta-analysis, she assessed the effectiveness of anti-tumor necrosis factor-alpha agents, highlighting inconsistent findings in their use for refractory sarcoidosis, urging for clearer guidelines regarding their application.
  • - Additionally, she conducted a systematic review on COVID-19, detailing clinical features and treatment in hospitalized patients to enhance understanding of this novel virus during its early outbreak phase.